Skip to main content
SpringerLink
Log in

Cytokines for the Treatment of Myelodysplastic Syndromes and Other Bone Marrow Failure States

  • Chapter
Clinical Applications of Cytokines and Growth Factors

Part of the book series: Developments in Oncology ((DION,volume 80))

  • 112 Accesses

Abstract

In this chapter the biological rationale and potential clinical utility of cytokines and colony stimulating factors (CSFs) for the treatment of myelodysplastic syndromes (MDS) and other bone marrow failure states such as aplastic anemia (AA), Fanconi’s Anemia, Diamond-Blackfan Syndrome and bone marrow suppression from drug therapy will be discussed. Since the application of CSFs has been more extensively studied in MDS and AA patients these disorders will be stressed. The rationale for the use of CSFs in these disorders is clear since they all represent difficult disease situations where bone marrow dysfunction or failure results in cytopenias. The goal of CSF therapy has been to correct those cytopenias without causing toxicity or progression of disease. In all of these clinical situations there are limitations to the efficacy of this form of therapy and these will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncogene expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88:4275–4287, 1996.

    PubMed  CAS  Google Scholar 

  2. Miyauchi J, Kelleher CA, Yang YC, et al. The effects of the three recombinant growth factors, IL3, GM-CSF and G-CSF on the blast cells of acute myeloblasts leukemia maintained in short-term suspension culture. Blood 76:657–663, 1987.

    Google Scholar 

  3. Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood 67:257–267, 1986.

    PubMed  CAS  Google Scholar 

  4. Vellenga E, Young DC, Wagner K, et al. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myelogenous leukemia. Blood 69:1771–1776, 1987.

    PubMed  CAS  Google Scholar 

  5. Greenberg PL. In vitro culture studies in myelodysplastic syndromes. Semin Oncol 19:34–46, 1992.

    PubMed  CAS  Google Scholar 

  6. Greenberg PL. The smoldering myeloid leukemic states: clinical and biological features. Blood 61:1035–1044, 1983.

    PubMed  CAS  Google Scholar 

  7. Block M, Jacobson LO, Bethard WF. Preleukemic acute leukemia. JAMA 152:1018–1021, 1953.

    Article  CAS  Google Scholar 

  8. Linman JW, Bagby GCJ. The preleukemic syndrome (hematopoietic dysplasia). Cancer 1978 42:854–864.

    Article  PubMed  CAS  Google Scholar 

  9. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199, 1982.

    PubMed  CAS  Google Scholar 

  10. Gosquen JE, Bennett JM. Classification and morphologic features of the myelodysplastic syndromes. Sem Oncol 19:4–13, 1992.

    Google Scholar 

  11. Mufti GJ, Stevens JR, Oscier DG, et al. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59:425–433, 1985.

    Article  PubMed  CAS  Google Scholar 

  12. Kerhofs N, Hermans J, Haak HL, et al. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 65:73–81, 1987.

    Article  Google Scholar 

  13. Foucar K, Langdon RM, Armitage JO, et al. Myelodysplastic syndromes: A clinical and pathological analysis of 109 cases. Cancer 56:553–561, 1985.

    Article  PubMed  CAS  Google Scholar 

  14. Greenberg P, Cox L, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088, 1997

    PubMed  CAS  Google Scholar 

  15. Nowell PC. Chromosome abnormalities in myelodysplastic syndromes. Sem Oncol 19:25–33, 1992.

    CAS  Google Scholar 

  16. Greenberg PL. In vitro culture techniques defining the biologic abnormalities in the myelodysplastic syndromes and myeloproliferative disoreders. Clinics in Haematol 15:973–993, 1986.

    CAS  Google Scholar 

  17. Boogaerts MA, Nelissen V, Roeland C, Goossens W. Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol 55:217–227, 1983.

    Article  PubMed  CAS  Google Scholar 

  18. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82:677–681, 1993.

    PubMed  CAS  Google Scholar 

  19. Anderson JE, Anasetti C, Appelbaum FR, et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 93:59–67, 1996.

    Article  PubMed  CAS  Google Scholar 

  20. Beran M, Kantarjian H, O’Brien S, et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88:2473–2479, 1996.

    PubMed  CAS  Google Scholar 

  21. Cines DB, Cassileth PA, Kiss JE. Danazol therapy in myelodysplasia. Ann Intern Med 103:58–60, 1985.

    PubMed  CAS  Google Scholar 

  22. Bagby GGJ, Gabourel JD, Linman JW. Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia): identification of responsive patients using in-vitro techniques. Ann Int Med 92:55–58, 1980.

    PubMed  Google Scholar 

  23. Cheson BD, Jasperse DM, Simon R, Freidman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4:1857–1864, 1986.

    PubMed  CAS  Google Scholar 

  24. Griffin JD, Spriggs D, Wisch JS, D.W. K. Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside. J Clin Oncol 3:982–991, 1985.

    PubMed  CAS  Google Scholar 

  25. Tricot G, DeBock R, Dekker AW, et al. Low dose arabinoside (Ara-C) in myelodysplastic syndromes. Br J Haematol 58:231–240, 1984.

    Article  PubMed  CAS  Google Scholar 

  26. Negrin RS, Haeuber DH, Nagler A, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I–II trial. Ann Int Med 110:976–984, 1989.

    PubMed  CAS  Google Scholar 

  27. Negrin RS, Haeuber DH, Nagler A, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36–43, 1990.

    PubMed  CAS  Google Scholar 

  28. Kobayashi Y, Okabe T, Ozawa K, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: A preliminary report. Am J Med 86:178–182, 1989.

    Article  PubMed  CAS  Google Scholar 

  29. Yoshida Y, Hirashima K, Asano S, Takaku F. A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 78:378–384, 1991.

    Article  PubMed  CAS  Google Scholar 

  30. Greenberg P, Taylor K, Larson R, et al. Phase III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS). Blood 82 suppl 1:196a., 1993

    Google Scholar 

  31. Thompson JA, Lee DJ, Kidd P, et al. Subcutaneous granulocyte-macrophage colony-stmulating factor in patients with myelodysplastic syndrome: Toxicity, pharmacokinetics and hematological effects. J Clin Oncol 7:629–637, 1989.

    PubMed  CAS  Google Scholar 

  32. Vadhan-Raj S, Keating M, LeMaistre A, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545–1552, 1987.

    Article  PubMed  CAS  Google Scholar 

  33. Herrmann F, Lindemann A, Klein H, et al. Effect of recombinant granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia 3:335–338, 1989.

    PubMed  CAS  Google Scholar 

  34. Ganser A, Volkers B, Greher J, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. Blood 73:31–37, 1989.

    PubMed  CAS  Google Scholar 

  35. Antin JH, Smith BR, Holmes W, et al. Phase I/II study of recombinant granulocyte-macrohage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 72:705–713, 1988.

    PubMed  CAS  Google Scholar 

  36. Vadhan-Raj S, Broxmeyer HE, Spitzer G, et al. Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood 74:1491–1498, 1989.

    PubMed  CAS  Google Scholar 

  37. Rosenfeld CS, Sulecki M, Evans C, Shadduck RK. Comparison of intravenous versus subcutaneouus recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia. Exp Hematol 19:272–277, 1991.

    Google Scholar 

  38. Willemze R, van der Lely N, Zwierzina H, et al. A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. Ann Hematol 64:173–180, 1992.

    Article  PubMed  CAS  Google Scholar 

  39. Schuster MW, Thompson JA, Larson RA, et al. Randomized trial of subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome or aplastic anemia. Proc Am Soc Clin Oncol A793, 1990.

    Google Scholar 

  40. Kuzrock R, Talpaz M, Estrov Z, et al. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241–1250, 1991.

    Google Scholar 

  41. Ganser A, Seipelt G, Lindemann A, et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455–462, 1990.

    PubMed  CAS  Google Scholar 

  42. Gordon MS, Nemunaitis J, Hoffman R, et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 85:3066–3076, 1995.

    PubMed  CAS  Google Scholar 

  43. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89:67–71, 1995.

    PubMed  CAS  Google Scholar 

  44. Stasi R, Brunetti M, Bussa S, et al. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin Lab Haematol 19:197–201, 1997.

    Article  PubMed  CAS  Google Scholar 

  45. Merchav S, Nielson OJ, Rosenbaum H, et al. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes. Leukemia 4:771–774, 1990.

    PubMed  CAS  Google Scholar 

  46. Greenberg PL, Negrin RS, Ginzton NL. G-CSF synergizes with erythropoietin for enhancing erythroid colony-formation in myelodysplastic syndromes. Blood 78(suppl 1):38a, 1991.

    Google Scholar 

  47. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87:4076–4081, 1996.

    PubMed  CAS  Google Scholar 

  48. Negrin RS, Stein R, Vardiman J, et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82:737–743, 1993.

    PubMed  CAS  Google Scholar 

  49. Hellstrom-Lindberg E, Birgegard G, Carlsson M, et al. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 11:221–228, 1993.

    Article  PubMed  CAS  Google Scholar 

  50. Hellstrom-Lindberg E, Negrin RS, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99:344–351, 1997.

    Article  PubMed  CAS  Google Scholar 

  51. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68–75, 1998.

    PubMed  CAS  Google Scholar 

  52. Bernell P, Stenke L, Wallvik J, Hippe E, Hast R. A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes. Leuk Res 20:693–699, 1996.

    Article  PubMed  CAS  Google Scholar 

  53. Runde V, Aul C, Ebert A, Grabenhorst U, Schneider W. Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes. Eur J Haematol 54:39–45, 1995.

    Article  PubMed  CAS  Google Scholar 

  54. Storb R, Leisenring W, Anasetti C, et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood 89:3890–3891, 1997.

    PubMed  CAS  Google Scholar 

  55. Vadhan-Raj S, Buescher S, Broxmeyer HE, et al. Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor. N Engl J Med 319:1628–1634, 1988.

    Article  PubMed  CAS  Google Scholar 

  56. Nissen C, Tichelli A, Gratwohl A, et al. Failure of recombinant human granulocyte-macrophage colony-stimulating factor therapy in aplastic anemia patients with very severe neutropenia. Blood 72:2045–2047, 1988.

    PubMed  CAS  Google Scholar 

  57. Champlin RE, Nimer SD, Ireland P, Oette DH, Golde DW. Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 73:694–699, 1989.

    PubMed  CAS  Google Scholar 

  58. Kojima S, Fukuda M, Miyajima Y, Matsuyama T, Horibe K. Treatment of aplastic anemia in children with recombinant human granulocyte colony-stimulating factor. Blood 77:937–941, 1991.

    PubMed  CAS  Google Scholar 

  59. Guinan EC, Sieff CA, Oette DH, Nathan DG. A phase I/II trial of recombinant granulocyte-macrophage colony-stimulating factor for children with aplastic anemia. Blood 76:1077–1082, 1990.

    PubMed  CAS  Google Scholar 

  60. Kojima S, Matsuyama T. Stimulation of granulopoiesis by high-dose recombinant human granulocyte colony-stimulating factor in children with aplastic anemia and very severe neutrophenia. Blood 83:1474–1478, 1994.

    PubMed  CAS  Google Scholar 

  61. Marsh JC, Socie G, Schrezenmeier H, et al. Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet 344:172–173, 1994.

    Article  PubMed  CAS  Google Scholar 

  62. Ganser A, Lindemann A, Seipelt G, et al. Effects of recombinant human interleukin-3 in aplastic anemia. Blood 76:1287–1292, 1990.

    PubMed  CAS  Google Scholar 

  63. Nimer SD, Pacquette RL, Ireland P, Resta D, Young D, Golde DW. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol 22:875–880, 1994.

    PubMed  CAS  Google Scholar 

  64. Bargetzi MJ, Gluckman E, Tichelli A, et al. Recombinant human interleukin-3 in refractory severe aplastic anaemia: a phase I/II trial. Br J Haematol 91:306–312, 1995.

    Article  PubMed  CAS  Google Scholar 

  65. Schrezenmeier H, Marsh JC, Stromeyer P, et al. A phase I/II trial of recombinant human interleukin-6 in patients with aplastic anemia. Br J Haematol 90:283–292, 1995.

    Article  PubMed  CAS  Google Scholar 

  66. Bessho M, Hirashima K, Asano S, et al. Treatment of the anemia of aplastic anemia patients with recombinant erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled trial. Multicenter Study Group. Eur J Haematol 58:265–272, 1997.

    Article  PubMed  CAS  Google Scholar 

  67. Bacigalupo A, Broccia G, Corda G, et al. Antilymphocyte globulin, cyclosporine, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood 85:1348–1353, 1995.

    PubMed  CAS  Google Scholar 

  68. Hord JD, Gay JC, Whitlock JA, et al. Long-term granulocyte-macrophage colony-stimulating factor and immunosuppression in the treatment of acquired severe aplastic anemia. J Pediatr Hematol Oncol 17:140–144, 1995.

    Article  PubMed  CAS  Google Scholar 

  69. Raghavachar A, Ganser A, Freund M, Heimpel H, Herrmann F, Schrezenmeier H. Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia. Cytokines Mol Ther 2:215–223, 1996.

    PubMed  CAS  Google Scholar 

  70. Shimizu T, Yoshida I, Eguchi H, Takahashi K, Inada H, Kato H. Sweet syndrome in a child with aplastic anemia receiving recombinant granulocyte colony-stimulating factor. J Pediatr Hematol Oncol 18:282–284, 1996.

    Article  PubMed  CAS  Google Scholar 

  71. Fukutoku M, Shimizu S, Ogawa Y, et al. Sweet’s syndrome during therapy with granulocyte colony-stimulating factor in a patient with aplastic anaemia. Br J Haematol 86:645–648, 1994.

    Article  PubMed  CAS  Google Scholar 

  72. Izumi T, Muroi K, Takatoku M, Imagawa S, Hatake K, Miura Y. Development of acute myeloblasts leukaemia in a case of aplastic anaemia treated with granulocyte colony-stimulating factor. Br. Haematol 87:666–668, 1994.

    Article  CAS  Google Scholar 

  73. Kemahli S, Canatan D, Uysal Z, Akar N, Cin S, Arcasoy A. GM-CSF in the treatment of Fanconi’s anaemia. Br J Haematol 87:871–872, 1994.

    Article  PubMed  CAS  Google Scholar 

  74. Rackoff WR, Orazi A, Robinson CA, et al. Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: a pilot study. Blood 88:1588–1593, 1996.

    PubMed  CAS  Google Scholar 

  75. Guinan EC, Lopez KD, Huhn RD, Felser JM, Nathan DG. Evaluation of granulocyte-macrophage colony-stimulating factor for treatment of panyctopenia in children with fanconi anemia. J Pediatr 124:144–150, 1994.

    Article  PubMed  CAS  Google Scholar 

  76. Dunbar CE, Smith DA, Kimball J, Garrison L, Nienhuis AW, Young NS. Treatment of Diamond-Blackfan anaemia with hematopoietic growth factors, granulocyte-macrophage colony stimulating factor and interleukin-3: sustained remissions following IL-3. Br J Haematol 79:316–321, 1991.

    Article  PubMed  CAS  Google Scholar 

  77. Gillio AP, Faulkner LB, Alter BP, et al. Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3. Blood 82:744–751, 1993.

    PubMed  CAS  Google Scholar 

  78. Ball SE, Tchernia G, Wranne L, et al. Is there a role for interleukin-3 in Diamond-Blackfan anaemia? Results of a European multicentre study. Br J Haematol 91:313–318, 1995.

    Article  PubMed  CAS  Google Scholar 

  79. Arribalzaga K, Garcia-Suarez J, Lopez-Rubio M, Krsnik I, Calero MA, Del Campo JF. Sustained granulocyte recovery after G-CSF in a patient with ticlopidine-induced severe aplastic anemia. Am J Hematol 50:313, 1995.

    Article  PubMed  CAS  Google Scholar 

  80. Chasen MR, Sarembock B, Meyers OL. Successful treatment of gold-induced aplastic anaemia with granulocyte macrophage colony stimulating factor. Br J Rheumatol 31:428–429, 1992.

    Article  PubMed  CAS  Google Scholar 

  81. Lopez-Karpovitch X, Ulloa-Aquirre A, von Eiff C, Hurtado-Monroy R, Alanis A. Treatment of methimazole-induced severe aplastic anemia with recombinant human granuloctye-monocyte colony-stimulating factor and corticosteroids. Acta Haematol 87:148–150, 1992.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Robert S. Negrin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Bone Marrow Transplant Program, Division of Hematology/Oncology, University of Florida College of Medicine, Shands Hospital, Gainesville, FL, 32610, USA

    John R. Wingard M.D. (Professor of Medicine, Director) (Professor of Medicine, Director)

  2. Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02115, USA

    George D. Demetri M.D. (Assistant Professor of Medicine) (Assistant Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Negrin, R.S. (1999). Cytokines for the Treatment of Myelodysplastic Syndromes and Other Bone Marrow Failure States. In: Wingard, J.R., Demetri, G.D. (eds) Clinical Applications of Cytokines and Growth Factors. Developments in Oncology, vol 80. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5013-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5013-6_18

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7277-6

  • Online ISBN: 978-1-4615-5013-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation